There were two RPE65-associated retinal dystrophy trials for the approval of voretigene neparvovec-ryzl: the US and EU-based trial for original approval (NCT00999609), and a subsequent trial conducted in Japan with commercial approval granted in 2023 (NCT04516369). Here, RPE65 is linked to Retinal dystrophy.